Mitiglinide Calcium is a drug for the treatment of type 2 diabetes; it is a highly selective KATP channel antagonist. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (KATP) channels in pancreatic beta-cells, and its early insulin release and short duration of action would be effective in improving postprandial hyperglycemia. Mitiglinide shows a higher selectivity for the beta-cell type of SUR1/Kir6.2 than the cardiac and smooth muscle types of K(ATP) channels in comparison with glibenclamide and glimepiride. Insulinotropic effect of mitiglinide is more potent than that of nateglinide, and mitiglinide surpassed in controlling postprandial hyperglycemia in normal and diabetic animals. In clinical trials, treatment with mitiglinide provided lasting improvement of postprandial hyperglycemia in Type 2 diabetic patients and decreased the fasting plasma glucose levels and HbA(1C) values[3]. Mitiglinide induces vasorelaxation via activation of Kv channels and SERCA (sarcoplasmic/endoplasmic reticulum Ca2+-ATPase) pump. However, the vasorelaxant effects of mitiglinide did not involve other K+ channels, Ca2+ channels, PKA/PKG signaling pathways, or the endothelium[4].
Japan
... 展开 >>
Nagoya-shi, Aichi, Japan
Fukuoka-shi, Fukuoka, Japan
Kurume-shi, Fukuoka, Japan
Sapporo-shi, Hokkaido, Japan
Kobe-shi, Hyogo, Japan
Kagoshima-shi, Kagoshima, Japan
Kumamoto-shi, Kumamoto, Japan
Osaki-shi, Miyagi, Japan
Minou-shi, Osaka, Japan
Osaka-shi, Osaka, Japan
Kamio-shi, Saitama, Japan
Koshigaya-shi, Saitama, Japan
Adachi-ku, Tokyo, Japan
Chuo-ku, Tokyo, Japan 收起 <<
Japan
... 展开 >>
Nagoya-shi, Aichi, Japan
Fukuoka-shi, Fukuoka, Japan
Kurume-shi, Fukuoka, Japan
Sapporo-shi, Hokkaido, Japan
Kobe-shi, Hyogo, Japan
Kagoshima-shi, Kagoshima, Japan
Kumamoto-shi, Kumamoto, Japan
Osaki-shi, Miyagi, Japan
Minou-shi, Osaka, Japan
Osaka-shi, Osaka, Japan
Kamio-shi, Saitama, Japan
Koshigaya-shi, Saitama, Japan
Adachi-ku, Tokyo, Japan
Chuo-ku, Tokyo, Japan 收起 <<
搜索
